Nanobodies are increasingly used as building blocks for multispecific antibodies, T-cell engagers, ADCs, CAR-T cells and radioligand therapies. But every existing discovery route forces a trade-off: binders are either human in sequence or behave like natural camelid VHHs (soluble, stable, single-domain), rarely both. In this webinar, Cyagen will show how HUGO-Nano™ mice produce VHH-like antibodies with a human framework, present validation and binder data, and outline partnership options that can shorten the path from target to lead for your single-domain antibody program.